| Bartholomew David Sak, MD | |
|
1500 E Sherman Blvd, Muskegon, MI 49444-1849 | |
| (231) 672-3883 | |
| (231) 672-3973 |
| Full Name | Bartholomew David Sak |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 1500 E Sherman Blvd, Muskegon, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093755167 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 4301068868 (Michigan) | Primary |
| 207R00000X | Internal Medicine | 4301068868 (Michigan) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Health Hackley Campus | Muskegon, MI | Hospital |
| Spectrum Health Ludington Hospital | Ludington, MI | Hospital |
| Spectrum Health Zeeland Community Hospital | Zeeland, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Specialty Services | 2365439544 | 79 |
| Spectrum Health Primary Care Partners | 4587568647 | 1585 |
| Sound Inpatient Physicians-michigan Pllc | 5395896849 | 213 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Spectrum Health Primary Care Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235188673 PECOS PAC ID: 4587568647 Enrollment ID: O20031121000091 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Aspirus Ironwood Hospital & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992704753 PECOS PAC ID: 9032013198 Enrollment ID: O20031121000096 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Mercy Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023056744 PECOS PAC ID: 8921996307 Enrollment ID: O20040308000687 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Mercy Specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629010384 PECOS PAC ID: 2365439544 Enrollment ID: O20040429000064 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013180181 PECOS PAC ID: 4486703170 Enrollment ID: O20090529000290 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Sound Inpatient Physicians-michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639311996 PECOS PAC ID: 5395896849 Enrollment ID: O20090624000252 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of Michigan - Tcs Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437794153 PECOS PAC ID: 9739517137 Enrollment ID: O20200318001589 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bartholomew David Sak, MD 1560 E Sherman Blvd Ste 240, Muskegon, MI 49444-1854 Ph: (231) 672-3883 | Bartholomew David Sak, MD 1500 E Sherman Blvd, Muskegon, MI 49444-1849 Ph: (231) 672-3883 |
News Archive
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.
Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.
› Verified 5 days ago
Kyle Nathaniel Turcic, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1500 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-672-2000 | |
Dr. Peyton Paul Faganel, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1675 Leahy St Ste 201a, Muskegon, MI 49442 Phone: 231-672-7800 | |
Jon Michael Carnahan, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-672-3883 Fax: 231-672-3973 | |
Dr. Sripriya Ganesan, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1675 Leahy St Ste 304b, Muskegon, MI 49442 Phone: 231-728-1695 | |
Matthew Anthony Wagner, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1500 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-672-2000 | |
Dr. William Patrick Hughes, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-672-3883 Fax: 231-672-3973 |